Risk of drug-induced congenital defects.

Marco De Santis, Gianluca Straface, Brigida Carducci, Anna Franca Cavaliere, L De Santis, A Lucchese, Am Merola, Alessandro Caruso

Risultato della ricerca: Contributo in rivistaArticolo in rivista

32 Citazioni (Scopus)


Defects attributable to drug therapy represent about 1% of congenital defects of known aetiology. This means that a precautionary attitude and correct use of drugs in fertile, and especially pregnant, women is a feasible form of prevention. Drugs currently in use with proven teratogenic effect number approximately 25, but new pharmaceutical drugs are constantly in preparation. Recognition of a drug-induced teratogenic effect is a complex procedure taking into account not only experimental animal data but also experience in humans. Considering that 40% of pregnancies are not planned, it follows that any drug with known or suspected teratogenic potential must be used only under strict medical control. Also, adequate knowledge on potential teratogenicity of a drug permits modification of therapy before conception. It goes without saying that any drug should be used during pregnancy only if it is essential, and it would be prudent to use only those where adequate information is provided and prior clinical experience is available. Teratology Information Services can assist both physicians and patients when any doubt exists.
Lingua originaleEnglish
pagine (da-a)10-19
Numero di pagine10
Stato di pubblicazionePubblicato - 2004


  • Congenital defect
  • Drug
  • Pregnancy
  • Teratogenic potential


Entra nei temi di ricerca di 'Risk of drug-induced congenital defects.'. Insieme formano una fingerprint unica.

Cita questo